In A Nutshell Researchers achieved 94% accuracy in identifying Alzheimer’s disease by analyzing bacterial infections, ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today ...

BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced another major independent validation of its AI and machine learning (ML) capabilities in a ...

Major depressive disorder (MDD) is a debilitating condition that affects more than 246 million people worldwide, yet ...

AI algorithms analyse complex medical images with speed and precision, supporting early disease detection.Radiology and ...

Predicting tumour progression is one of the major challenges in oncology. Scientists at the University of Geneva (UNIGE) and ...

Explore how biochemistry, microbiology, and pathology collaborate in cancer care for early detection, personalized treatment, and survival monitoring.

However, little is known about how these pollutants interact during early development, particularly in sensitive organs such as the eye. Based on these challenges, it is necessary to conduct in-depth ...

A new study from Karolinska Institutet shows that damage to small blood vessels in the hereditary disease CADASIL may disrupt ...

Shareholder/Analyst Call February 5, 2026 3:30 PM ESTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...

Nine in 10 people worldwide have been infected with Epstein-Barr virus (EBV). | Nine in 10 people worldwide have been ...

Predicting tumor progression is one of the major challenges in oncology. Scientists at the University of Geneva (UNIGE) and the Ludwig Institute for Cancer Research have discovered that neutrophils, a ...